NCT04160052View on ClinicalTrials.gov

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeTherapy-Related Myelodysplastic Syndrome

Interventions

DRUG

Azacitidine

Given SC or IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04160052 - Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter